Abstract
Introduction: To date few evidences are available on the risk of hepatic decompensation (HD) related to portal hypertension (PH) after therapy with new direct-acting antivirals (DAAs) in patients with HCV-related advanced chronic liver disease (ACLD). Furthermore, the predictive role of liver (LSM) and spleen (SSM) stiffness measurement after DAA therapy is still debated. We previously reported that SSM 54 kPa was able to predict HD in untreated HCV patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
